Boston Scientific price target lowered to $100 from $105 at RBC Capital

RBC Capital lowered the firm’s price target on Boston Scientific (BSX) to $100 from $105 and keeps an Outperform rating on the shares. The stock rose after the company’s Q1 earnings and sales beats, and the management’s guidance cut was “prudent” with Q2 seen as the trough quarter, the analyst tells investors in a research note. BSX is seeing increasing competitive pressures in EP, but the U.S. outlook looks conservative, while standalone Watchman weakness is offset by strong concomitant demand, RBC added.